title: Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
authors.forename: Kashef
authors.initials: K
authors.lastname: Ijaz
authors.forename: Peter D
authors.initials: PD
authors.lastname: McElroy
authors.forename: John
authors.initials: J
authors.lastname: Jereb
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Navin
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Castro
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin